Oncolytic Herpes Virus rRp450 Shows Efficacy in Orthotopic Xenograft Group 3/4 Medulloblastomas and Atypical Teratoid/Rhabdoid Tumors.

Mol Ther Oncolytics · 2017 · PMC5472147 · PMID 28649600

Europe PMC DOI

hedged sentence

0.0611

closest p · 1.2× alpha

0.0611

boldest claim

The sentences

a strong trendp = 0.0611so close (0.05 < p ≤ 0.1)

While co-treatment failed to reach strictly defined statistical significance, it did produce a strong trend toward increased survival (p = 0.0611), and 50% (5/10) of the animals displayed CR compared with no animals (0/5) in the rRp450-alone-treated group.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.